Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Citadel Advisors LLC's stake in Acrivon Therapeutics, Inc. fell below 5% (Schedule 13G/A)
Event Mar 31, 2026 · Filed May 15, 2026
Citadel Advisors LLC's stake in Acrivon Therapeutics, Inc. fell below 5%, 0 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G/A).
- Stake
- 0%
- Shares
- 0
- Intent
- Passive
- What changed
- Fell below 5%
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Citadel Advisors LLC | 0% | 0 |
| Citadel Advisors Holdings LP | 0% | 0 |
| Citadel GP LLC | 0% | 0 |
| Citadel Securities LLC | 0% | 13 |
| Citadel Securities Group LP | 0% | 13 |
| Citadel Securities GP LLC | 0% | 13 |
| Kenneth Griffin | 0% | 13 |
Source
Related
- Acrivon Therapeutics, Inc.
- Citadel Advisors LLC
- Acrivon Therapeutics, Inc. shareholders
- Schedule 13G · Citadel Advisors LLC · Nov 21, 2025
- Schedule 13G/A · Citadel Advisors LLC · Nov 14, 2025
- Schedule 13G/A · Citadel Advisors LLC · May 15, 2025
- Form 4 · Miller Mary · Oct 7, 2026
- Form 4 · Levin Michaela · Sep 2, 2026
- Form 4 · Blume-Jensen Peter · Aug 27, 2026
- Form 4 · Peterson Katharine · Aug 20, 2026
- Form 4 · Miller Mary · Aug 20, 2026